Literature DB >> 12631625

Interleukin 10 blocks matrix metalloproteinase-2 and membrane type 1-matrix metalloproteinase synthesis in primary human prostate tumor lines.

Mark E Stearns1, Min Wang, Youji Hu, Fernando U Garcia, Johng Rhim.   

Abstract

Insulin-like growth factor (IGF) I has been shown previously to up-regulate matrix metalloproteinase-2 (MMP-2) production, whereas the interleukin (IL) 10/IL-10 receptor axis has been found to down-regulate MMP-2 synthesis in tumor cells. In this paper, we showed that IL-10 activation of the IL-10 receptor blocked MMP-2 and membrane type 1 (MT1) -MMP transcription and protein synthesis in nonimmortalized primary human prostate cell strains (i.e., HPCA-10a and HPCA-10c) derived from high-grade cancer. Northern blots, Western blots, and ELISAs showed that IL-10 suppressed IGF-I induction of MMP-2 and MT1-MMP mRNA synthesis in these cell strains (P < 0.001). Inhibition studies with IL-10 and IGF-I receptor antibodies plus transfections experiments with IL-10 sense, and IGF-I receptor antisense constructs confirmed these results. Finally, transient transfection experiments and chloramphenicol acetyltransferase assays with different regions of the 5' promoter region of the MMP-2 gene (-1659 to -555 bp) additionally showed that IGF-I stimulated p53-dependent plasmid catecholamine acetyltransferase activity and that IL-10 blocked IGF-I-induced plasmid catecholamine acetyltransferase activity. Electrophoretic mobility shift assays revealed that IL-10 induced protein(s) binding to a putative "silencer element" (-1309 to -555 fragment) downstream of the p53 binding site (-1649 to -1640). The data show that IL-10 blocks IGF-I activation of MMP-2 and MT1-MMP mRNA expression and protein synthesis in primary prostate cell strains.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631625

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  8 in total

1.  Therapeutic failure in American cutaneous leishmaniasis is associated with gelatinase activity and cytokine expression.

Authors:  A C Maretti-Mira; M P de Oliveira-Neto; A M Da-Cruz; M P de Oliveira; N Craft; C Pirmez
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

2.  Metalloproteinase's activity and oxidative stress in mild cognitive impairment and Alzheimer's disease.

Authors:  Sagrario Martín-Aragón; Paloma Bermejo-Bescós; Juana Benedí; Emanuela Felici; Pedro Gil; José Manuel Ribera; Angel Ma Villar
Journal:  Neurochem Res       Date:  2008-07-10       Impact factor: 3.996

3.  Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Raymond Lai; George Z Rassidakis; L Jeffrey Medeiros; Latha Ramdas; Andre H Goy; Cathy Cutler; Yasushi Fujio; Keita Kunisada; Hesham M Amin; Frederic Gilles
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

4.  Proteinases as virulence factors in Leishmania spp. infection in mammals.

Authors:  Mariana Silva-Almeida; Bernardo Acácio Santini Pereira; Michelle Lopes Ribeiro-Guimarães; Carlos Roberto Alves
Journal:  Parasit Vectors       Date:  2012-08-07       Impact factor: 3.876

5.  The interleukin-10 promoter polymorphism rs1800872 (-592C>A), contributes to cancer susceptibility: meta-analysis of 16,785 cases and 19,713 controls.

Authors:  Qi Ding; Ying Shi; Bo Fan; Zhijiang Fan; Li Ding; Feng Li; Wenjian Tu; Xiaohua Jin; Jing Wang
Journal:  PLoS One       Date:  2013-02-27       Impact factor: 3.240

6.  Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells.

Authors:  Jun Sun
Journal:  J Signal Transduct       Date:  2010-07-20

7.  MMP1-1607 polymorphism increases the risk for periapical lesion development through the upregulation MMP-1 expression in association with pro-inflammatory milieu elements.

Authors:  Ana Paula Favaro Trombone; Franco Cavalla; Elcia Maria Varize Silveira; Camile Bermejo Andreo; Carolina Favaro Francisconi; Angélica Cristina Fonseca; Ariadne Letra; Renato Menezes Silva; Gustavo Pompermaier Garlet
Journal:  J Appl Oral Sci       Date:  2016 Jul-Aug       Impact factor: 2.698

8.  Cutaneous wound healing: canine allogeneic ASC therapy.

Authors:  Nathaly Enciso; Luis Avedillo; María Luisa Fermín; Cristina Fragío; Concepción Tejero
Journal:  Stem Cell Res Ther       Date:  2020-06-29       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.